Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Necrosis Factor Superfamily Member 14 (TNFSF14)
- Target
- TNFSF14
- Molecular classification
- Tumor Necrosis Factor Ligand Superfamily, Type II transmembrane protein, Ligand
01
Overview
LIGHT, also known as Tumor Necrosis Factor Superfamily Member 14 (TNFSF14) or CD258, is a type II transmembrane protein and a member of the TNF ligand family. It acts as an immune checkpoint molecule with roles in both innate and adaptive immunity. LIGHT binds to HVEM and LTβR, influencing various cellular processes including T cell activation, NK cell function, apoptosis, and vascular normalization. It is being explored as a therapeutic target in cancer immunotherapy.
- Other names
- LIGHTCD258
02
Mechanism of action
Agonism or antagonism of HVEM and LTβR receptors, modulation of NF-κB signaling
03
Biological functions
Immune costimulationImmune checkpoint regulationApoptosis inductionVessel normalizationT lymphocyte activation/proliferationNK cell activationRegulation of vascular normalizationRestriction of neovascularization
04
Disease associations
CancerInflammationAutoimmunity
05
Safety considerations
Potential for immune-related adverse events due to broad immune modulationPotential for off-target effects due to expression on various cell types
06
Biomarkers
Prognosis in lung carcinomaPrognosis in breast carcinomaPrognosis in cervical cancerPrognosis in prostate cancerPrognosis in GBMTherapeutic response prediction in various cancers
Beyond the preview
Go deeper on Tumor Necrosis Factor Superfamily Member 14 (TNFSF14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor Necrosis Factor Superfamily Member 14 (TNFSF14).